Erasca(ERAS) - 2023 Q4 - Annual Results

Exhibit 99.1 Erasca Reports Fourth Quarter 2023 and Full Year 2023 Business Updates and Financial Results Gained global registrational clarity for naporafenib and achieved key clinical milestones for naporafenib, ERAS- 007, and ERAS-801 Multiple data readouts expected in 2024 for naporafenib (SEACRAFT-1), ERAS-007 (HERKULES-3), and ERAS-801 (THUNDERBBOLT-1) and planned initiation of pivotal SEACRAFT-2 trial Robust balance sheet with cash, cash equivalents, and marketable securities of $322 million as of Dec ...